Royal Bank Of Canada Aadi Bioscience, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.46 - $2.31 $798 - $1,263	547 Added 147.84%	917 $1,000
Q1 2024 Nov 05, 2024	SELL	$1.59 - $2.44 $869 - $1,334	-547 Reduced 59.65%	370 $0
Q1 2024 May 15, 2024	SELL	$1.59 - $2.44 $6,072 - $9,318	-3,819 Reduced 91.17%	370 $0
Q4 2023 Feb 14, 2024	BUY	$1.97 - $5.41 $2,176 - $5,978	1,105 Added 35.83%	4,189 $8,000
Q3 2023 Nov 14, 2023	BUY	$4.84 - $7.13 $1,650 - $2,431	341 Added 12.43%	3,084 $14,000
Q2 2023 Aug 14, 2023	BUY	$6.84 - $8.56 $13,050 - $16,332	1,908 Added 228.5%	2,743 $18,000
Q1 2023 May 15, 2023	SELL	$6.85 - $13.0 $8,452 - $16,042	-1,234 Reduced 59.64%	835 $6,000
Q4 2022 Feb 14, 2023	BUY	$11.99 - $14.5 $22,685 - $27,434	1,892 Added 1068.93%	2,069 $26,000
Q3 2022 Nov 14, 2022	BUY	$12.03 - $14.22 $1,154 - $1,365	96 Added 118.52%	177 $3,000
Q2 2022 Aug 15, 2022	SELL	$11.57 - $17.92 $32,338 - $50,086	-2,795 Reduced 97.18%	81 $1,000
Q1 2022 May 16, 2022	BUY	$16.65 - $24.97 $47,885 - $71,813	2,876 New	2,876 $49,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $46.7M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.